Copyright
©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Mar 21, 2008; 14(11): 1641-1642
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1641
Published online Mar 21, 2008. doi: 10.3748/wjg.14.1641
Novel therapeutic approaches for hepatocellulcar carcinoma: Fact and fiction
Yuan-Yuan Zhang, Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China
Harry Hua-Xiang Xia, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Correspondence to: Dr. Yuan-Yuan Zhang, Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China. zhangyy@sibs.ac.cn
Telephone: +86-21-55664332
Fax: +86-20-65650149
Received: January 29, 2008
Revised: February 21, 2008
Published online: March 21, 2008
Revised: February 21, 2008
Published online: March 21, 2008
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for 80%-90% of this class of malignancy. So far, understanding of its pathogenesis and effective therapeutic methods are rather limited. In this issue, 11 invited review articles are published to address current advance of underlying molecular mechanisms for the deve-lopment of HCC, and novel therapeutic approaches for HCC. This series of review articles provide an in-depth unders-tanding of HCC that has led to or may lead to the development of novel therapies for HCC.
Keywords: Hepatocellular carcinoma; Pathogenesis; Treatment